Therapeutic opportunities for regulatory T-cell enhancing approaches
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxad009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von David F Tough und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Research Unit, GSK, Medicines Research Centre, Stevenage, Hertfordshire, UK. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Autoimmunity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The immune system plays a critical role in protecting the host against infection but is subject to numerous levels of control that are necessary to prevent pathological, tissue-damaging responses. Inappropriate inflammatory immune responses to self-antigens, innocuous commensal microorganisms, or environmental antigens can lead to chronic, debilitating, and degenerative diseases. Regulatory T cells have an essential, non-redundant, and dominant function in preventing pathological immune responses, as shown by the development of systemic fatal autoimmunity in humans and animals with a genetic deficiency in regulatory T cells. In addition to controlling immune responses, there is a growing understanding that regulatory T cells also contribute directly to tissue homeostasis by promoting tissue regeneration and repair. For these reasons, the prospect of enhancing regulatory T-cell numbers and/or function in patients represents an appealing therapeutic opportunity with potential applications in many diseases, including some where the pathological role of the immune system has only recently been recognized. Approaches to enhance regulatory T cells are now starting to be explored in clinical studies in humans. This review series brings together papers highlighting the Treg-enhancing approaches that are most advanced clinically and examples of therapeutic opportunities based on our growing understanding of regulatory T-cell functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immunology Research Unit, GSK, Medicines Research Centre, Stevenage, Hertfordshire, UK.
- Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
Zitieren
APA
Tough, D. F., & Lombardi, G. (2023). Therapeutic opportunities for regulatory T-cell enhancing approaches. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad009
Vancouver
Tough DF, Lombardi G. Therapeutic opportunities for regulatory T-cell enhancing approaches. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad009
BibTeX
@article{Tough2023,
author = {Tough, David F and Lombardi, Giovanna},
title = {Therapeutic opportunities for regulatory T-cell enhancing approaches},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxad009}
}
EUVIMED